Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?

The Lancet Oncology

Volumn 10, Issue 10, 2009, Pages 933-935

  Amir, Eitan ^a   Clemons, Mark ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADVANCED CANCER; BONE METASTASIS; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL TRIAL; FALSE NEGATIVE RESULT; HUMAN; LETTER; METASTASIS; NON INVASIVE PROCEDURE; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR BIOPSY;

BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 70349391998     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70295-5     Document Type: Letter

References (14)

1. Brennan M.J., Donegan W.L., and Appleby D.E. The variability of estrogen receptors in metastatic breast cancer. Am J Surg 137 (1979) 260-262
2. Li B.D., Byskosh A., Molteni A., et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57 (1994) 71-77
3. Regitnig P., Schippinger W., Lindbauer M., et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203 (2004) 918-926
4. Simmons C., Miller N., Geddie W., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 20 (2009) 1499-1504
5. Amir E., Freedman O., Simmons C., et al. Biopsy confirmation of metastatic breast cancer: interim results of a prospective biopsy study. Breast Cancer Res 11 (2009) S20
6. Amir E., Ooi W.S., Simmons C., et al. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) 20 (2008) 763-768
7. Mann G.B., Fahey V.D., Feleppa F., et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23 (2005) 5148-5154
8. Bussolati G., and Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61 (2008) 1184-1192
9. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
10. Yaziji H., Taylor C.R., Goldstein N.S., et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 16 (2008) 513-520
11. Peterson L.M., Mankoff D.A., Lawton T., et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49 (2008) 367-374
12. Dehdashti F., Mortimer J.E., Trinkaus K., et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113 (2009) 509-517
13. Dijkers E.C., Kosterink J.G., Rademaker A.P., et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50 (2009) 974-981
14. Müller V., Stahmann N., Riethdorf S., et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11 (2005) 3678-3685